Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COR
stocks logo

COR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
86.03B
+5.57%
4.074
+9.22%
79.95B
+5.95%
4.918
+11.26%
85.42B
+5.9%
4.346
+8.64%
Estimates Revision
The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2026, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by 15.35%.
Revenue Estimates for FY2026
Revise Downward
down Image
-0.56%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+0.85%
In Past 3 Month
Stock Price
Go Up
up Image
+15.35%
In Past 3 Month
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 337.630
sliders
Low
361.00
Averages
393.78
High
417.00
Current: 337.630
sliders
Low
361.00
Averages
393.78
High
417.00
Wells Fargo
Overweight
maintain
$354 -> $405
2025-11-11
Reason
Wells Fargo
Price Target
$354 -> $405
2025-11-11
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Cencora to $405 from $354 and keeps an Overweight rating on the shares. The firm says the company reported fairly strong Q4 results and introduced attractive FY26 guidance. Core growth in U.S. Healthcare remains outstanding and absent material deceleration would seem to suggest potential for additional positive estimate revisions, Wells adds.
JPMorgan
NULL -> Overweight
maintain
$344 -> $417
2025-11-11
Reason
JPMorgan
Price Target
$344 -> $417
2025-11-11
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Cencora to $417 from $344 and keeps an Overweight rating on the shares. The firm updated the company's model.
TD Cowen
Buy
maintain
$350 -> $400
2025-11-10
Reason
TD Cowen
Price Target
$350 -> $400
2025-11-10
maintain
Buy
Reason
TD Cowen raised the firm's price target on Cencora to $400 from $350 and keeps a Buy rating on the shares. The firm said they remain confident in the shares following F4Q25 and the introduction of its FY26 guidance where they continue to see upside.
UBS
Buy
maintain
$380 -> $415
2025-11-07
Reason
UBS
Price Target
$380 -> $415
2025-11-07
maintain
Buy
Reason
UBS raised the firm's price target on Cencora to $415 from $380 and keeps a Buy rating on the shares. The initial guidance for the U.S. Healthcare Solutions segment EBIT is doable, if not conservative, the analyst tells investors in a research note.
Deutsche Bank
NULL -> Buy
maintain
$322 -> $371
2025-11-07
Reason
Deutsche Bank
Price Target
$322 -> $371
2025-11-07
maintain
NULL -> Buy
Reason
Deutsche Bank raised the firm's price target on Cencora to $371 from $322 and keeps a Buy rating on the shares.
Mizuho
NULL -> Outperform
maintain
$340 -> $380
2025-11-06
Reason
Mizuho
Price Target
$340 -> $380
2025-11-06
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Cencora to $380 from $340 and keeps an Outperform rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 18.98, compared to its 5-year average forward P/E of 14.46. For a more detailed relative valuation and DCF analysis to assess Cencora Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PE
14.46
Current PE
18.98
Overvalued PE
16.70
Undervalued PE
12.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.58
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.29
Undervalued EV/EBITDA
8.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.14
Current PS
0.00
Overvalued PS
0.16
Undervalued PS
0.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2472.49% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

COR News & Events

Events Timeline

(ET)
2025-11-05
06:35:14
Cencora projects FY26 adjusted EPS between $17.45 and $17.75, in line with consensus of $17.48
select
2025-11-05
06:33:34
Cencora Increases Quarterly Dividend by 9% to 60 Cents per Share from 55 Cents
select
2025-11-05
06:32:09
Cencora announces Q4 adjusted EPS of $3.84, surpassing consensus estimate of $3.79
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-03NASDAQ.COM
Cencora (COR) Receives Upgrade to Buy: Reasons Behind the Decision

  • Cencora's Upgrade: Cencora (COR) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimates Impact: The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements, making it a valuable tool for investors.

  • Zacks Rank System: The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% receiving a "Strong Buy" or "Buy" rating, suggesting potential for market-beating returns.

  • Future Earnings Projections: For the fiscal year ending September 2026, Cencora is expected to earn $17.66 per share, with analysts raising estimates by 1.1% over the past three months, reflecting an improving business outlook.

[object Object]
Preview
4.5
12-02NASDAQ.COM
Significant ETF Withdrawals: USMV, MCK, COR, WM

  • 52-Week Range of USMV: The USMV ETF has a 52-week low of $83.99 and a high of $95.59, with the last trade recorded at $94.31.

  • Understanding ETFs: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), impacting the underlying assets.

  • Disclaimer: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

[object Object]
Preview
7.5
11-28NASDAQ.COM
CVS Health Achieves MBR Enhancement: Will Further Advancements Follow?

  • CVS Health Performance: CVS Health's medical benefit ratio (MBR) improved to 92.8% in Q3 2025 from 95.2% the previous year, driven by the absence of significant premium deficiency reserves and better performance in the Government business, despite challenges from Medicare Part D changes and individual exchange risks.

  • Cigna's New Health Plan: Cigna Group launched Clearity by Cigna Healthcare, a copay-only health plan aimed at enhancing transparency and simplicity in healthcare decisions through AI-powered digital tools and upfront pricing.

  • Cencora's Investment Plans: Cencora announced a $1 billion investment through 2030 to expand its U.S. pharmaceutical distribution network, including a new distribution center in Ohio and enhanced operations in Alabama and California.

  • Market Outlook for CVS Health: CVS Health shares have increased by 27.2% over the past six months, outperforming the industry, and analysts remain optimistic about the company's future earnings, maintaining a Zacks Rank #3 (Hold).

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cencora Inc (COR) stock price today?

The current price of COR is 337.63 USD — it has increased 0.69 % in the last trading day.

arrow icon

What is Cencora Inc (COR)'s business?

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

arrow icon

What is the price predicton of COR Stock?

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cencora Inc (COR)'s revenue for the last quarter?

Cencora Inc revenue for the last quarter amounts to 83.73B USD, increased 5.92 % YoY.

arrow icon

What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?

Cencora Inc. EPS for the last quarter amounts to -1.75 USD, decreased -8850.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cencora Inc (COR)'s fundamentals?

The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2026, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by 15.35%.
arrow icon

How many employees does Cencora Inc (COR). have?

Cencora Inc (COR) has 51000 emplpoyees as of December 05 2025.

arrow icon

What is Cencora Inc (COR) market cap?

Today COR has the market capitalization of 65.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free